Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Reach of its Drug Delivery Technology Through Newly Inked Agreements with Beverage Developer BevNology

  • Drug delivery technology innovator Lexaria Bioscience has developed a patented technology showing superiority in animal and human testing as a means of improving existing drug brands’ performance and establishing new solutions for unmet medical needs
  • The company recently announced agreements with beverage developer BevNology to expand production capabilities for Lexaria’s own growing list of B2B clientele and empowering BevNology to offer DehydraTECH products with active ingredients derived from hemp including CBD under BevNology and partnered brands 
  • The technology is called DehydraTECH — improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery  
  • Lexaria also recently announced an agreement with Ireland’s Anodgen Bioceuticals that allows Anodgen to manufacture and distribute DehydraTECH processed cannabinoid API powders within Europe including the UK, Australia and New Zealand

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has built the reputation of its patented DehydraTECH drug delivery technology through a growing data set of potential medicinal applications and through an expanding list of licensing agreements with third-party companies interested in its potential for cannabidiol (“CBD”)-based products. 

Lexaria’s patented DehydraTECH technology transforms a wide variety of orally and topically administered products into enhanced solutions that make the APIs more rapidly available and effective at lower doses while adding zero chemical byproducts. 

Among the licensing partnerships announced by the company are recent agreements with beverage developer BevNology and Ireland API manufacturer and distributor Anodgen Bioceuticals. 

The BevNology collaboration was announced June 21 and not only includes a commercial license agreement for products with active ingredients derived from hemp under BevNology’s brand, but also a manufacturing operating agreement utilizing BevNology’s new, custom-built state-of-the-art processing facility outside Atlanta.

“These agreements build on a long standing and very successful product development consulting relationship between Lexaria and the expert scientists and personnel at BevNology,” Lexaria CEO Chris Bunka stated in announcing the BevNology development (https://cnw.fm/6it3Q). “BevNology’s formulation and production capabilities are class leading and we are confident that our new relationship with our trusted partner will propel new and exciting growth opportunities for both companies.”

The manufacturing agreement will help Lexaria broaden its production capabilities for its own growing list of B2B clientele interested in purchasing DehydraTECH-powered active ingredients for consumer packaged-goods brands.  Lexaria has already installed all required commercial DehydraTECH manufacturing equipment at the facility. 

The licensing agreement addresses powdered DehydraTECH formulations and liquid formulations that tend toward BevNology’s particular expertise. Both elements of the agreement are non-exclusive, except that the liquid formulations have limited exclusivity in the United States and complete exclusion in Japan, the Republic of Korea, and the People’s Republic of China. 

The Anodgen licensing agreement was announced earlier in the month and includes a five-year non-exclusive DehydraTECH license for powdered CBD-based products in Europe including the United Kingdom, Australia, and New Zealand. 

Under the license, Anodgen can use DehydraTECH not only for making and selling medical application CBD products but also pharmaceutical applications for psychoactive cannabinoids (https://cnw.fm/JjYBn). Anodgen is building a new facility in Ireland and expects to be fully operational later this year, creating the potential for long-term use of DehydraTECH for the pharmaceutical market. 

Independent third-party testing has evidenced DehydraTECH’s ability to enhance the performance of a variety of pharmaceutical and wellness industry products and has led to a pre-Investigational New Drug (“IND”) meeting with the U.S. Food and Drug Administration (“FDA”) to file DehydraTECH-CBD as a prospective registered treatment for hypertension this year (https://cnw.fm/M6RAk). 

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Grants Licenses to Three Companies for the Month of June; Looks to Follow Through with its Scheduled 2022 Clinical Studies

  • Lexaria sold Premier Wellness Science Co. exclusive rights to use its patented DehyraTECH(TM) in Japan in a variety of CBD products
  • Valcon Medical A/S also signed an agreement with Lexaria to use its platform for medical cannabis applications in Europew
  • AnodGen Bioceuticals received a pharmaceutical license to use the platform for manufacturing and distributing CBD API powders in Europe, Australia, and New Zealand

Lexaria Bioscience (NASDAQ: LEXX) kicked off the month by announcing an exclusive license to Premier Wellness Science Co. for the use of its patented DehydraTECH(TM) technology in Japan in a variety of CBD products. Announced on June 3, this license would cover oral or non-liquid products and can be used in topical, hair-care, lip-care, and cosmetics segments. 

Premier is a wholesale and retail marketer of cosmetics and health foods in Japan. It also provides information and consulting services to entities in the anti-aging, beauty, and health industries. In addition, Premier also offers market research, data collection, and analysis for its clients. The arrangement with Lexaria includes minimum payments of $4.5 million to be paid over the first five years of the deal to maintain exclusivity, with the first payments being made beginning September 1, 2022.

On June 2, 2022, Lexaria announced having signed an agreement granting Valcon Medical A/S rights to use the DehydraTECH platform for medical cannabis applications in Europe. The products subject to this license were classified as non-registered medical products and authorized through country-level programs or EU Commission-registered cannabis products.

Valcon plans to use this platform in bulk powders, solid oral dosage forms, powder-filled capsules, compressed tablets, pills, oral melts, and topical creams and lotions. This non-exclusive license will attract milestone fees from Valcon upon completing batch validation and marketing authorization application approvals. Valcon is a European CMO that is good manufacturing practice (“GMP”) certified. It is licensed in Denmark to manufacture medical cannabis and works with partners to provide contract processing and bulk extract services.

On June 8, 2021, Lexaria announced having granted a pharmaceutical license for using its DehydraTECH platform to AnodGen Bioceuticals. AnodGen, a contract manufacturing organization (“CMO”), manufactures and distributes active pharmaceutical ingredients for the pharmaceutical industry by focusing on plant-based medicine. 

With Lexaria’s license, AnodGen will manufacture and distribute cannabidiol (“CBD”) active pharmaceutical ingredient (“API”) powders in Europe, Australia, and New Zealand. The license covers both pharmaceutical and medical product applications for psychoactive cannabinoids and medical applications for non-psychoactive cannabinoids. In addition, it can also be extended to third-party companies to use in their products.

Lexaria is confident that with these newly awarded licenses and ongoing research in hypertension and nicotine, it is preparing for increased global utilization of its technology and for increased cashflows in its journey towards profitability.

In an interview with Unboxing Biotech (https://cnw.fm/ocMfu) Chris Bunka, Lexaria’s CEO, shared his optimism for the company. In addition, he highlighted the company’s progress and the strides it would make as time progresses. More specifically, he acknowledged the advancement made so far regarding DehydraTECH and potential hypertension treatment, along with the company tapping into the nicotine replacement therapy (“NRT”) market.

Lexaria held its 2022 annual meeting on May 31, 2022. One of the key agendas in the meeting was the appointment of directors and an auditor for the current and future financial years. In the meeting represented by approximately half of all shareholders shares, all the nominated directors and auditor Davidson & Company LLP were approved. This would set the stage for Lexaria’s material partnerships that would define the month of June, as described in a recent Zacks report and interview covering Lexaria (https://cnw.fm/7mOLv).

Going forward, Lexaria looks to follow through with its clinical studies, advance its research and forge even more partnerships with other key players in the CBD space. In addition, the company looks to leverage its unique value proposition to grow its revenue and create value for its shareholders.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Enters Strategic Manufacturing, License Agreements with BevNology

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced the signing of two agreements with Atlanta-based BevNology LLC. According to the update, the first manufacturing operating agreement expands production capabilities for Lexaria’s own growing list of business-to-business (“B2B”) clientele interested in purchasing DehydraTECH-powered active ingredients for consumer packaged-goods brands. A new, state-of-the-art processing facility custom-built by BevNology is operational that increases and broadens production capacity and is currently serving Lexaria’s corporate clients. The second commercial license agreement empowers BevNology to offer DehydraTECH products with active ingredients derived from hemp including cannabidiol (“CBD”) under BevNology and partnered brands. “These agreements build on a long-standing and very successful product development consulting relationship between Lexaria and the expert scientists and personnel at BevNology,” said Chris Bunka, CEO of Lexaria. “BevNology’s formulation and production capabilities are class leading and we are confident that our new relationship with our trusted partner will propel new and exciting growth opportunities for both companies.”

To view the full press release, visit https://cnw.fm/28PAc

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 25 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Expanding Array of API Enhancements Through Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Patented Drug Technology Bodes Well for New Patient Solutions

  • Drug bioavailability enhancement technology developer Lexaria Bioscience is working to increase the number of potential new solutions to unmet medical needs and improving existing treatments for other chronic conditions
  • Lexaria’s patented DehydraTECH solution transforms a wide variety of orally and topically administered products into enhanced solutions that make the active pharmaceutical ingredients (“APIs”) more rapidly available and effective at lower doses 
  • DehydraTECH-enhanced products have also demonstrated the ability to cross the blood-brain barrier through fatty acid transport proteins 
  • The company’s ongoing series of tests of different DehydraTECH-enhanced products has led to a pre-IND filing with the FDA for a prospective registered treatment for hypertension, while other anticipated potential therapies target seizures, nicotine addiction and erectile dysfunction

The COVID pandemic that roiled the world’s healthcare systems during the past two years (and appears to be hospitalizing an increasing number of patients again (https://cnw.fm/iEIXl) revealed a marked demand for repurposing existing drugs for unanticipated treatments, particularly prior to the provisional development of various targeted vaccines to combat the novel coronavirus (https://cnw.fm/cnOfh). 

New data analysis has revealed the potential for several existing biopharma products to be repositioned to treat patients with unmet medical needs, potentially opening the way for dozens of new solutions to chronic medical conditions (https://cnw.fm/QwudW).

At the same time, drug technology innovator Lexaria Bioscience (NASDAQ: LEXX) is finding ways to make available pharmaceuticals and wellness products more effective at doing what they do to treat patient needs, helping to expand the range of potential solutions to chronic health concerns and unmet medical needs.

Lexaria’s patented DehydraTECH product is a technology used to increase the bioavailability of drugs administered orally or transdermally while adding zero chemical byproducts. 

The company’s ongoing testing is delivering data that demonstrates the DehydraTECH-enhanced products’ ability to take effect faster and more potently in placebo-controlled and double-blinded human clinical trials. 

As an example of some of Lexaria’s testing, a series of studies have advanced its investigation of DehydraTECH-CBD from lab animal to human subject stage as a potential treatment for hypertension (heart disease-related high blood pressure) and the company is pursuing a pre-Investigational New Drug (“IND”) meeting with the U.S. Food and Drug Administration (“FDA”) to file its product as a prospective registered treatment this year (https://cnw.fm/sQMAP).

Another series of tests involve the DehydraTECH-nicotine oral pouch. Smoked nicotine is the world’s leading avoidable cause of death, but non-combusted oral nicotine is dramatically less harmful. is being advanced as a non-inhaled but rapidly available Lexaria’s DehydraTECH-nicotine oral pouch is being tested this summer in a human clinical study against existing leading product brands including Zyn (Swedish Match) and ON! (Altria). Lexaria expects its DehyraTECH processed and purified nicotine to work faster than leading brands, delivering higher levels of consumer satisfaction.

Another R&D program is pitting DehydraTECH-CBD against generic CBD and Epidiolex to evaluate DehydraTECH’s ability to improve treatments for epileptic seizures – that testing will be ongoing throughout much of 2022. And if all that isn’t enough, antiviral research shows DehydraTECH enhanced versions of Remdesivir and Ebastine were effective at inhibiting COVID’s SARS- CoV-2 virus and improving their delivery into bloodstream, as well as that of Darunavir and Efavirenz, which are used in treating HIV / AIDS and regarded as potential COVID therapies (https://cnw.fm/I18cp).

With the expanding reach of the company’s research, Lexaria is optimistic its patented technology for delivering APIs into the bloodstream and across the blood-brain barrier with reduced liver metabolization — adaptable to multiple ingestible product formats such as tablets, capsules, oral suspensions and mouth-melts — will prove disruptive to the pharmaceutical industry. 

All planned Lexaria operations are fully funded through Q3 2023 at this time. 

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Ground-Breaking Studies Opening ‘Doors Previously Closed to Disruptive New Technology’

Lexaria Bioscience Corp. (NASDAQ: LEXX) understands the shortcomings of orally administered drugs and is developing DehydraTECH(TM), a drug delivery technology that solves challenges such as poor water solubility and membrane permeability, limited absorption and unwanted tastes. “The company began developing DehydraTECH in 2014 and has since strengthened the technology as well as broadened its possible applications… Lexaria has also conducted in vitro and in vivo human and/or animal studies that have evidenced the technology’s ability to mask unwanted tastes, improve the speed of onset, increase bioavailability and brain absorption, and lower dosing – thereby reducing drug administration costs – of APIs,” a recent article reads. “So far, Lexaria has explored how DehydraTECH improves APIs, not limited to, cannabidiol (‘CBD’), oral nicotine and antiviral drugs, with the company describing its oral nicotine investigations as ‘ground-breaking studies to open doors previously closed to disruptive new technology, including the possibility of potent and fast-acting ingestible products that avoid the lung diseases and cancers caused by inhalation of combusted molecules common in smoking.’”

To view the full article, visit https://cnw.fm/SHNT7

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 25 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Initiates Communication with the FDA Concerning Potential Treatment for Hypertension; Out-Licenses Its DehydraTECH Technology to International Markets

  • Lexaria, a global innovator of drug delivery platforms, recently filed a pre-IND meeting request letter with the FDA, initiating communication regarding the development of its DehydraTECH-CBD as a treatment for hypertension
  • The company has been undertaking preparatory programs in readiness for the meeting, as well as an IND application filing
  • The pre-IND meeting will confirm the details of the company’s IND-enabling program
  • Lexaria also announced it had licensed its DehydraTECH technology to AnodGen, with the announcement following similar out-licensing agreements with Valcon Medical and Premier Science

Early last September, global innovator Lexaria Bioscience (NASDAQ: LEXX) was pleased to announce it had formally commenced the process toward an Investigational New Drug (“IND”) application filing with the Food and Drug Administration (“FDA”) with its DehydraTECH(TM)-processed cannabidiol (“CBD”) for the treatment of hypertension (https://cnw.fm/rDcfI).

According to the September 8 news release, Lexaria had retained the services of an expert regulatory affairs and quality assurance consulting group that would help prepare the company for a pre-IND meeting with the FDA. The group would also assist Lexaria with designing the requisite non-clinical, clinical, and related product development IND-enabling work/program meant to be finalized before the company files its IND application.

Through the intervening period, Lexaria has made progress bringing it closer to achieving these goals, recently reporting it had filed a pre-IND meeting request letter with the FDA. The request, to which the federal agency had already responded and set a target date of July 30, 2022 (subject to the fulfillment of certain conditions), formally initiated communication with the FDA concerning the development of DehydraTECH-CBD as a treatment for hypertension (https://cnw.fm/SNVqc).

“We are excited to take this important first regulatory step with the FDA for the development of our DehydraTECH-CBD for the treatment of hypertension,” commented Lexaria President John Docherty. “Submission of this request letter initiates formal communication with the FDA regarding our IND clinical trial plans in order to help define the critical path for clinical development and marketing approval of our potentially very significant new hypertension therapeutic.”

The pre-IND meeting is intended to confirm the details and acceptability of Lexaria’s IND-enabling work, which is set to be completed after the meeting has been held. This work has been made possible by the company’s growing body of evidence showing DehydraTECH-CBD’s capacity to potentially treat hypertension. 

Through its successfully completed studies – HYPER-H21-1, HYPER-H21-2, and HYPER-H21-3 – Lexaria has not only demonstrated that DehydraTECH-CBD lowers the human blood pressure relative to placebo and reduces arterial stiffness but also that it does not cause any adverse effects. According to the company’s recent statement, efficacy and the lack of negative side effects are the two main goals of FDA-registered clinical studies.

Following the pre-IND meeting and the completion of the IND-enabling development program, Lexaria expects to then proceed with its full IND application filing expected in late 2022 or early 2023. 

Meanwhile, the company also celebrated another milestone that saw it expand the list of licensees. In a recent announcement, Lexaria reported that its wholly owned subsidiary, Lexaria Pharmaceutical Corp., had awarded a five-year, non-exclusive DehydraTECH license to AnodGen Bioceuticals of Ireland (https://cnw.fm/ZrHuV).

The license allows AnodGen, a newly established contract manufacturing organization business, to manufacture and distribute DehydraTECH-processed cannabinoid active pharmaceutical ingredient (“API”) powders within Europe (including the UK), Australia, and New Zealand. The license also covers pharmaceutical and medical product applications for psychoactive cannabinoids and medical product applications for non-psychoactive cannabinoids. AnodGen can also manufacture and sell the API powders to third-party companies for their own products, subject to the fulfillment of specific conditions. On its part, Lexaria will receive royalty fees for all API powders sold that utilize the DehydraTECH drug delivery technology.

This licensing agreement comes on the heels of two similar agreements that saw Lexaria Pharmaceutical Corp. grant a European and UK license to medical cannabis manufacturer Valcon Medical A/S (https://cnw.fm/eHkdp) and a license to Premier Wellness Science Co. Ltd to deploy DehydraTECH within the Japanese non-pharmaceutical market (https://cnw.fm/cfkkH). 

“We are focused on larger national and international applications for DehydraTECH, primarily but not entirely in the pharmaceutical sector. These are our areas of interest that we expect will provide significant revenue streams over time…,” commented Lexaria CEO Chris Bunka in a January letter to shareholders (https://cnw.fm/pcj9E). With the series of out-licenses announced recently, Lexaria appears to be inching closer to realizing this goal.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) and the Budding Alternative Nicotine Market

  • The nicotine pouch market is projected to reach $21.84 billion in 2027, up from $2.33 billion in 2020, representing a CAGR of 30.7%
  • The smokeless tobacco products sector is expected to post a CAGR of 7.2% over the forecast period (2018-2025)
  • Lexaria, through its patented DehydraTECH technology, is tapping into this important alternative nicotine sector 
  • Its management is confident that its research and technology development investment will pay off and provide greater consumer satisfaction.

In 2019, it was estimated that at least 1.1 billion people globally smoked cigarettes regularly. 780 million, representing 71% of the global smoking population, noted that they wanted to quit. Their resolve to quit smoking has seen a significant decline in cigarette sales and a steady rise in nicotine alternatives, which experts project will carry on for the foreseeable future (https://cnw.fm/UyBtW). 

For one, the nicotine pouch market has grown significantly and is estimated to reach $21.84 billion in 2027, up from $2.33 billion in 2020, representing a CAGR of 30.7%. The nicotine replacement therapy (“NRT”) market size, on the other hand, is projected to reach $147.9 billion by 2028, representing a CAGR of 16.3% over the 2021 to 2028 forecast period (https://cnw.fm/YyNlg). 

Lexaria Bioscience (NASDAQ: LEXX) acknowledges the transference from smoking cigarettes to nicotine alternatives. Through its patented DehydraTECH technology, it looks to tap into this 853 billion dollar industry and stamp its position as the undisputed industry leader.

Since Lexaria began the development of DehydraTECH back in 2014, it has seen its application in various areas, including but not limited to antivirals, cannabinoids, vitamins, and non-steroidal anti-inflammatory drugs (“NSAIDs”). However, nicotine is showing great promise, with Lexaria exploring the oral mucosal nicotine market that is an integral part of the smokeless tobacco products sector which is expected to grow at a CAGR of 7.2% from 2018 to 2025 (https://cnw.fm/Yrt30). 

In a move that sought to prove DehydraTECH’s superiority, Lexaria conducted an oral nicotine absorption study in 2021. The research showed that Lexaria’s nicotine delivered via an oral pouch product dispensed enough nicotine levels in blood plasma in four minutes, as concentration-matched controls did in 45 minutes. In addition, peak levels of DehydraTECH nicotine proved to be approximately ten times higher than the peak level of the controls (https://cnw.fm/GNae9).

Lexaria is looking to build on these findings with the latest human study slated to begin in the summer of 2022. The research will compare Lexaria’s DehydraTECH-nicotine pouch performance to existing leading brands on shelves in the United States. The company is optimistic that this study will help it differentiate itself, its brand, and its product in the market, ultimately growing its market share and creating value for its shareholders.

With key industry players such as Altria Group, British American Tobacco Industries, Philip Morris International, and GlaxoSmithKline PLC embracing a transition to a smoke-free future, Lexaria isn’t being left behind. Instead, it recognizes the existing opportunity and is capitalizing on its DehydraTECH technology to set itself apart from its peers and aggressively push its brand in the market.

Lexaria’s management is confident that its research investment and technology development will pay off significantly with time. But, more importantly, they note that it will provide much greater consumer satisfaction.

“Our technology was ten to twenty times faster in delivering comparable levels of nicotine into bloodstream than the peak of the concentration-matched controls and went on to far exceed their total delivery, which should provide much greater consumer satisfaction,” reckoned Chris Bunka, Lexaria’s Chief Executive Officer (“CEO”).

“Performance gains of this magnitude could be of great significance in enabling the oral pouch product category to offer improved nicotine satiety and effectiveness, with a goal of one day rendering pulmonary administration practices like smoking and vaping as obsolete,” he added.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Grants DehydraTECH(TM) License to Ireland-Based AnodGen Bioceuticals

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced the awarding of a five-year, non-exclusive DehydraTECH(TM) license from its wholly-owned subsidiary, Lexaria Pharmaceutical Corp., to AnodGen Bioceuticals of Ireland. According to the update, the awarded license is valid for the manufacturing and distribution of DehydraTECH-processed cannabinoid active pharmaceutical ingredient (“API”) powders within Europe including the U.K., Australia and New Zealand; including pharmaceutical and medical product applications for psychoactive cannabinoids and medical product applications for non-psychoactive cannabinoids. AnodGen, which has the right to manufacture and sell these API powders to third party companies for their own products designated by a national regulator as a medical product, drug, nutraceutical, pharmaceutical or biopharmaceutical, will pay royalty fees to Lexaria for all API powders sold that utilize the DehydraTECH technology. “This strategic alliance with Lexaria Bioscience Corp. underscores the focus of AnodGen to ‘Bring Science to Life,’ in addition to our research and APIs,” said Dr Slimane Aboulkacem, chairman and founding member of AnodGen Bioceuticals.

To view the full press release, visit https://cnw.fm/i8kzk

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 25 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Takes First Regulatory Step with FDA for Development of DehydraTECH-CBD in Treating Hypertension

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that it has successfully filed a pre-Investigational New Drug (“IND”) meeting request letter with the U.S. Food and Drug Administration (“FDA”). According to the update, the FDA has already responded to and confirmed Lexaria’s filing and has provided a target date of July 30, 2022, subject to certain conditions being met. “We are excited to take this important first regulatory step with the FDA for the development of our DehydraTECH-CBD for the treatment of hypertension,” said John Docherty, president of Lexaria. “Submission of this request letter initiates formal communication with the FDA regarding our IND clinical trial plans, in order to help define the critical path for clinical development and marketing approval of our potentially very significant new hypertension therapeutic.”

For more information, view the full press release

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 25 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Awards Exclusive License to Japan’s Premier Wellness Science Co.

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has awarded licensing of its proprietary DehydraTECH(TM) offering for development in Japan to Premier Wellness Science Co. Ltd, a wholly owned subsidiary of Premier Anti-Aging Co. Ltd. LEXX announced that Premier is purchasing exclusive rights to DehydraTECH technology for the Japanese nonpharmaceutical market; the company will use the tech in oral liquid and nonliquid products, as well as for topical, hair-care, lip-care and cosmetics products. According to the announcement, Lexaria will receive minimum payments of $4,527,500 over the next five years, as all well as royalties from the sales of products made with DehydraTECH, which the company anticipates could be significantly greater than the minimum payments. In addition, the two companies agreed to explore the possibility of R&D collaborations. An official from Premier noted that the company partnered with Lexaria based on DehydraTECH’s superior performance and the extensive data available through Lexaria’s years of testing. “Lexaria is delighted to be working with Premier Wellness Science, which we expect will dominate the newly opening Japanese market for CBD-based products,” said Lexaria CEO Chris Bunka in the press release. “Premier and Lexaria share similar philosophies, such as the provision of world-leading products created through scientific advantages and placing the consumer’s needs ahead of our own. We could not have found a better partner with which to introduce DehydraTECH-enabled products to the Japanese markets.”

For more information, view the full press release

About Lexaria Bioscience Corp.

Lexaria Bioscience’s patented drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 25 patents granted and more than 50 patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.